Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
- CAS Registry Number
- 1216941-48-8
- Molecular formula
- C40H43N7O7S
- Molecular weight
- 765.9 g/mol
- Drug class
- Hepatitis C virus (HCV) NS3/4A serine protease inhibitordirect-acting antiviral
- Mechanism of action
- Reversibly binds the active centre of the HCV NS3/4A protease and prevents protease-mediated cleavage of the viral polyprotein, disrupting maturation of viral proteins needed for replication. It is used in combination regimens; ritonavir increases paritaprevir exposure through CYP3A4 inhibition.
- Indications / reported uses
- Used only as part of labelled combination regimens for chronic hepatitis C, such as ombitasvir/paritaprevir/ritonavir with or without dasabuvir; indication and availability are regimen- and jurisdiction-specific.
Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ombitasvir-paritaprevir-ritonavir · https://www.ema.europa.eu/en/medicines/human/EPAR/viekirax
Identification source: PubChem record (CID 45110509). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.